Citations

Clear

12 citation(s) found for "Schnitzler, L".

The deep brain stimulation response network in Parkinson’s disease operates in the high beta band
Bahners, Bahne H. , Goede, Lukas L. , Zvarova, Patricia , Meyer, Garance M. , Butenko, Konstantin , Lofredi, Roxanne , Schaper, Frédéric , Neudorfer, Clemens, Pijar, Julianna , Madan, Savir , Hart, Lauren A., Sure, Matthias , Steina, Alexandra , Rassoulou, Fayed, Hartmann, Christian J, Hirschmann, J., Vesper, Jan , Faust, K., Sander, Tilmann H., Neumann, Wolf‐Julian , Miller, Kai, Schnitzler, Alfons, Kühn, Andrea A. , Florin, Esther , Horn, Andreas, Schaper, Frederic L W V J , Hirschmann, Jan , Neumann, Wolf-Julian , Kühn, Andrea A , Florin, Esther , Horn, Andreas , Goede, Lukas , Rajamani, Nanditha , Neudorfer, Clemens , Hollunder, Barbara , Butz, Markus , Schneider, Gerd‐Helge , Sander, Tilmann H. , Fox, Michael , Miller, Kai J. , Schnitzler, Alfons

Mayo Clinic

Brain | November 25, 2025 | Volume: 149 | Issue: 7 | Pages: 2395-2408

10.1093/brain/awaf445 | PMID 41645667 Get It

Abstract Deep brain stimulation (DBS) of the subthalamic nucleus improves motor symptoms in patients with Parkinson’s disease. Using functional MRI, optimal DBS response networks have been characterized. However, neural activity associated with Parkinsonian symptoms is magnitudes faster than what can be resolved by this method. Although both spatial and temporal domains of these networks appear crucial, no single study has yet investigated both domains simultaneously. Here, we aimed at closing this gap by analysing electrophysiological data from a total of n = 127 hemispheres. Using subthalamic local field potentials that were recorded concurrently alongside whole-brain magnetoencephalography in a multi-centre cohort of patients who underwent subthalamic DBS for the treatment of Parkinson’s disease (n = 100 hemispheres), we analysed the DBS response network in both spatial and temporal domains. In every cortical vertex, cortico-subthalamic coupling was correlated with stimulation outcomes. This network spatially resembled functional MRI-based findings (R = 0.40, P = 0.039) and explained significant amounts of variance in clinical outcomes (βstd = 0.30, P = 0.002), whereas theta–alpha and low beta coupling did not show significant associations with DBS response (theta–alpha: βstd = −0.02, P = 0.805; low beta: βstd = −0.08, P = 0.426). The ‘optimal’ high beta coupling map was robust when subjected to various cross-validation designs (10-fold cross-validation: R = 0.29, P = 0.009; split-half design: R = 0.31, P = 0.026) and was able to predict outcomes across DBS centres [R = 0.74; P(1) = 8.9 × 10−5]. We identified a DBS response network that resembles the previously defined MRI network and operates in the high beta band. Maximal connectivity to this network was associated with optimal DBS outcomes and was able to cross-predict clinical improvements across DBS surgeons and centres.
Economic Impact of Dementia After Kidney Transplantation: A Matched Cohort Analysis
Lentine, Krista L. , Swee, Melissa L. , Cheungpasitporn, Wisit , Xiao, Huiling , McAdams‐DeMarco, Mara , Chen, Yusi , Bae, Sunjae , Segev, Dorry L. , Caliskan, Yasar , McAdams-DeMarco, Mara , Bae, Sunjae , Segev, Dorry L , Axelrod, David , Schnitzler, Mark , Cheungpasitporn, Wisit , Axelrod, David A. , Schnitzler, Mark A.

Mayo Clinic

Clinical Transplantation | June 2, 2025 | Volume: 39 | Issue: 6 | Pages: No page available

10.1111/ctr.70189 | PMID 40454832 Get It

ABSTRACT Background Kidney disease significantly increases the risk of dementia, including among kidney transplant (KTx) recipients. To date, the cost implications of dementia after KTx are not well described. Methods We performed a retrospective cohort study of US Renal Data System (USRDS) data (2006–2020) to estimate cost of care for ≥65‐year‐old Medicare insured KTx recipients (2006–2020) with newly diagnosed dementia ( n = 3285), compared to propensity‐matched controls without dementia ( n = 6570). KTx recipients age 65+ years with post‐KTx dementia were identified by diagnosis codes, and costs were computed based on payments on Medicare claims. Average costs per month, marginal costs per month, and cumulative costs were compared after dementia diagnosis versus after the equivalent time post‐KTx in controls. Results Dementia was diagnosed at a mean of 5.1 ± 3.4 years post‐KTx. Patients' characteristics were well matched in cases versus controls, including age (mean: 70.1 vs. 69.9 years), sex (38.4% vs. 37.9% women), race (23.7% vs. 22.2% African American), and cause of ESKD (45.4% vs. 43.7% diabetes). Over 4 years post‐KTx, dementia was associated with reduced survival (27% vs. 68%) along with $66 145 (95% CI $51 560‐$78 489) higher Medicare spending. Average monthly costs in dementia patients reached a maximum of $12 713 and exceeded the cost of unaffected patients by up to $9789 per month. Conclusions Post‐KTx dementia dramatically increased resource utilization and reduced post‐KTx surivival. These findings highlight the need for care pathways that better integrate cognitive health assessment and management into the care of KTx candidates and recipients.
Impact of Native Kidney Disease on Post-Transplant Cancer Development
Cheungpasitporn, Wisit, Çalışkan, Yaşar , Axelrod, David A. , Li, Ruixin , Cheungpasitporn, Wisit , Schnitzler, Mark A. , Alhamad, Tarek , Chang, Su‐Hsin , Lentine, Krista L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 636-636

10.1681/asn.20213210s1636b Get It

Immunosuppression and Incident Cancer Risk in Older Kidney Transplant Recipients
Cheungpasitporn, Wisit, Ahn, JiYoon B. , Bunnapradist, Suphamai , Bae, Sunjae , Lentine, Krista L. , Çalışkan, Yaşar , Cheungpasitporn, Wisit , Li, Ruixin , Schnitzler, Mark A. , McAdams‐DeMarco, Mara , Dharnidharka, Vikas R. , Segev, Dorry L. , Hess, Gregory P. , Axelrod, David A.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 650-650

10.1681/asn.20213210s1650b Get It

Immunosuppression, Osteoporosis, and Fractures in Younger and Older Adults After Kidney Transplantation
Cheungpasitporn, Wisit, Ahn, JiYoon B. , Bae, Sunjae , Bunnapradist, Suphamai , Randall, Henry B. , Lentine, Krista L. , Kuppachi, Sarat C. , Li, Ruixin , Çalışkan, Yaşar , Cheungpasitporn, Wisit , Schnitzler, Mark A. , McAdams‐DeMarco, Mara , Dharnidharka, Vikas R. , Segev, Dorry L. , Hess, Gregory P. , Axelrod, David A.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 631-631

10.1681/asn.20213210s1631a Get It

Abstract 145: CRISPRi-Perturb-seq In Endothelial Cells Links Atherosclerosis Risk Loci To Novel Klf2/4 Regulatory Genes
Gupta, Rajat M. , Schnitzler, Gavin R., Kang, Helen , Fang, Shi, Lee, Vivian S. , Zheng, Tony, Barry, Aurelie , Angom, Ramcharan Singh , Lee-Kim, Vivian, Ma, Rosa, Zhou, Ronghao , Mukhopadhyay, Debabrata , Engreitz, J

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.145 Get It

Introduction: Genome-wide association studies (GWAS) have discovered >300 associations for CAD. Few loci are functionally characterized and may represent new mechanisms of disease. Hypothesis: Can an unbiased transcriptional screen for the >2000 candidate GWAS genes in endothelial cells (ECs) identify causal genes and disease-relevant pathways at CAD GWAS loci. Methods: We applied CRISPRi-Perturb-seq to knock down expression of genes within 500 Kb of coronary artery disease GWAS loci (2,300 genes in total) and measure their transcriptomic effects using single-cell RNA-seq. Validation of candidate causal genes was conducted in primary human ECs and zebrafish. Results: We identified 50 programs of co-expressed genes, which represent core cellular pathways (i.e. ribosome biogenesis) and 13 EC-specific pathways such as flow response and angiogenesis. The EC-specific programs show the greatest contribution to CAD heritability. 5 EC-specific programs have the greatest number of GWAS candidate genes. We find that 43 of 306 CAD GWAS signals converge onto these 5 gene programs, and all are regulated by genes in the cerebral cavernous malformations (CCM) pathway—which coordinates KLF2/4 transcriptional responses in endothelial cells, but has not been linked to CAD risk. The strongest regulator of these programs is TLNRD1 , which we show is a new CAD gene and novel regulator of the CCM pathway. TLNRD1 loss-of-function alters actin organization and barrier function in endothelial cells in vitro , and heart development in zebrafish in vivo . Conclusions: High-throughput functional analysis of 2,300 genes proximal to CAD GWAS loci prioritized pathways—such as angiogenesis and EC migration—that are regulated by multiple risk SNPs. Our study identifies new genes that likely influence risk for CAD, identifies convergence of CAD genes into certain pathways in endothelial cells, and prioritizes study of genes in the CCM-signaling pathway for contribution to CAD risk.
N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression
Boogert, Marjolein A.W. van den, Ali, Lubna, Chong, Patrick L.W., Loregger, Anke, Kroon, Jeffrey , Schnitzler, Johan G., Schimmel, Alinda W.M., Peter, Jorge , Levels, J.H.M. , Steenbergen, Gerry, Dallinga‐Thie, Geesje M. , Wevers, Ron A. , Kuivenhoven, Jan Albert , Hand, Nicholas J. , Zelcer, Noam , Stroes, Erik S.G. , Lefeber, Dirk J. , Holleboom, Adriaan G. , Larsen, Lars E., Kuil, Sacha Daniëlle , Chong, Patrick L.E., Morava, Éva , Rader, Daniel J

Mayo Clinic

Circulation | May 23, 2019 | Volume: 140 | Issue: 4 | Pages: 280-292

10.1161/circulationaha.118.036484 | PMID 31117816 Get It

Background: The importance of protein glycosylation in regulating lipid metabolism is becoming increasingly apparent. We set out to further investigate this by studying patients with type I congenital disorders of glycosylation (CDGs) with defective N-glycosylation. Methods: We studied 29 patients with the 2 most prevalent types of type I CDG, ALG6 (asparagine-linked glycosylation protein 6)–deficiency CDG and PMM2 (phosphomannomutase 2)–deficiency CDG, and 23 first- and second-degree relatives with a heterozygous mutation and measured plasma cholesterol levels. Low-density lipoprotein (LDL) metabolism was studied in 3 cell models—gene silencing in HepG2 cells, patient fibroblasts, and patient hepatocyte-like cells derived from induced pluripotent stem cells—by measuring apolipoprotein B production and secretion, LDL receptor expression and membrane abundance, and LDL particle uptake. Furthermore, SREBP2 (sterol regulatory element-binding protein 2) protein expression and activation and endoplasmic reticulum stress markers were studied. Results: We report hypobetalipoproteinemia (LDL cholesterol [LDL-C] and apolipoprotein B below the fifth percentile) in a large cohort of patients with type I CDG (mean age, 9 years), together with reduced LDL-C and apolipoprotein B in clinically unaffected heterozygous relatives (mean age, 46 years), compared with 2 separate sets of age- and sex-matched control subjects. ALG6 and PMM2 deficiency led to markedly increased LDL uptake as a result of increased cell surface LDL receptor abundance. Mechanistically, this outcome was driven by increased SREBP2 protein expression accompanied by amplified target gene expression, resulting in higher LDL receptor protein levels. Endoplasmic reticulum stress was not found to be a major mediator. Conclusions: Our study establishes N-glycosylation as an important regulator of LDL metabolism. Given that LDL-C was also reduced in a group of clinically unaffected heterozygotes, we propose that increasing LDL receptor–mediated cholesterol clearance by targeting N-glycosylation in the LDL pathway may represent a novel therapeutic strategy to reduce LDL-C and cardiovascular disease.
Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition
Jani, Prachi, Vissing, Megan Brinkworth, Ahmed, Salman , Sluzevich, Jason C. , Aulakh, Sonikpreet , Alegria, Victoria R., Ailawadhi, Meghna, Chanan‐Khan, Asher , Vissing, Megan B, Alegria, Victoria, Sluzevich, Jason C , Ailawadhi, Sikander

Mayo Clinic

Journal of Oncology Practice | March 20, 2018 | Volume: 14 | Issue: 6 | Pages: 387-388

10.1200/jop.18.00050 | PMID 29558252 Get It

Faculty Opinions recommendation of Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 12, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732271714.793540231 Get It

Faculty Opinions recommendation of Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 12, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962466.793540232 Get It